Navigation Links
Selexys Pharmaceuticals Completes $23M Equity Financing and Signs Agreement With Global Pharmaceutical Company

OKLAHOMA CITY, Sept. 19, 2012 /PRNewswire/ -- Selexys Pharmaceuticals, Corp., announced today that it has successfully completed a $23 million Series A equity financing, led by MPM Capital.  Additionally, Selexys entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase 2 clinical study in patients with sickle cell disease.  Including upfront, acquisition and milestone payments, the agreement with Novartis could reach up to $665 million.

The Series A financing includes a new major investor, MPM Capital. Concurrent with the investment, Selexys also announced the addition of Todd Foley, Managing Director of MPM Capital, to the Selexys Pharmaceuticals Board of Directors.

"Patients with sickle cell disease endure great suffering and frequent hospitalization due to painful vasoocclusive crises. Chronic blockade of P-selectin function with SelG1 may improve clinical outcomes and lower the associated cost of patient care," said Dr. Scott Rollins, President and CEO of Selexys. "We are excited to welcome MPM and Novartis and look forward to a productive partnership." The combination of the Novartis agreement and the closing of the Series A financing will allow Selexys to advance the SelG1 program through a large Phase 2 clinical study in sickle cell patients and will also fund a second program at Selexys, an anti-PSGL-1 antibody, through a Phase I clinical study.

"Vasoocculsive crises represent a significant healthcare problem for sickle cell disease patients, and we were impressed by the early data for SelG1 and the quality of the Selexys team," said Todd Foley, Managing Director of MPM Capital. "We are pleased to be a part of this successful financing structure, and I look forward to working closely with Selexys."

About SelG1

SelG1 is an investigational humanized monoclonal antibody directed against P-selectin, a key member of the adhesion molecule family known as the selectins. In preclinical studies, inhibition of P-selectin has been shown to effectively prevent vasoocclusion by blocking critical cell-cell interactions that drive this process. Therapeutic blockade of P-selectin may therefore reduce or prevent vasoocclusive crises in patients with sickle cell disease.

"SelG1 is a first-in-class therapeutic approach for the treatment of vasoocclusive crisis in sickle cell disease," stated Dr. Russell Rother, Selexys Executive Vice-president and COO. "Results from the recently completed Phase I safety study indicate that SelG1 is safe and well tolerated in healthy human subjects, and we are now eager to investigate its safety and efficacy in the sickle cell disease patient population."

The SelG1 program for sickle cell disease is supported by Small Business Innovation Research (SBIR) fast-track award #5R44HL093893-02 and #2R44HL093893-03 through the National Heart, Lung and Blood Institute.

About Selexys Pharmaceuticals

Selexys Pharmaceuticals, Corp., is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of inflammation, thrombosis and metastasis across a broad range of severe diseases.  Selexys is also developing an antibody directed against PSGL-1 for the treatment of Crohn's disease, multiple myeloma, and other inflammatory disorders. Selexys is headquartered in Oklahoma City, OK.  For additional information please visit our website at

About MPM Capital

MPM Capital is one of the world's largest life science-dedicated venture investors. With committed capital under management in excess of $2.6 billion, MPM Capital is uniquely structured to invest globally in healthcare innovation.

SOURCE Selexys Pharmaceuticals, Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology:
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners is ... sequencing and genomics experience, as Vice President of North American Capital Sales at ... for leading the sales team in the commercialization of the HTG EdgeSeq system and ...
Breaking Medicine News(10 mins):